Cantor Fitzgerald came out and expressed concerns around the Magnificent Seven group, saying the stocks are “vulnerable.” ...

Cantor Fitzgerald reaffirmed its Overweight rating and $170.00 price target on Ascendis Pharma (NASDAQ:ASND) shares, currently trading at $119.49. The firm's analyst highlighted the early adoption of ...

Cantor Fitzgerald reaffirmed its Overweight rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a consistent price target of $480.00. According to InvestingPro data, Vertex, a prominent ...

Will the Senate GOP confirm controversial picks like Tulsi Gabbard and RFK Jr.? Here’s the hearings schedule and list of ...

In a report released today, Andres Coello from Scotiabank maintained a Buy rating on AST SpaceMobile (ASTS – Research Report), with a price ...

Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Onto ...

President Trump pumped the brakes last week on a pledge to shut down an import tax exemption for cheap consumer goods from ...

ORIC Pharmaceuticals Inc. (NASDAQ: ORIC) shares rose 12% following a recommendation from Cantor Fitzgerald to buy shares amid a possible leak of encouraging clinical trial data. Analyst Prakhar ...

A billionaire financier who lost more than 650 employees and his brother in the September 11 attacks, Howard Lutnick is US ...

Cantor Fitzgerald analyst Deepak Mathivanan maintained a Buy rating on Pinterest (PINS – Research Report) today and set a price target of ...